Efficacy of a paclitaxel-eluting biliary metal stent with sodium caprate in malignant biliary obstruction: a prospective randomized comparative study

Abstract Backgrounds The placement of a self-expandable metal stent (SEMS) is widely used in patients with unresectable malignant biliary obstructions, but SEMSs are susceptible to occlusion by tumor ingrowth or overgrowth. The efficacy and safety of a novel paclitaxel-eluting biliary metal stent incorporating sodium caprate (MSCPM-III) were compared prospectively with those of a covered metal stent (CMS) in patients with malignant biliary obstructions. Methods Patients with unresectable distal malignant biliary obstructions (n = 106) were prospectively enrolled in this study at multiple treatment centers. Stents were placed endoscopically: MSCPM-III in 54 patients and CMS in 51 patients. The patients received systemic chemotherapy regimens according to their disease characteristics. Results The two groups did not differ significantly in basic characteristics or mean follow-up period. Stent occlusion occurred in 14 patients who received MSCPM-III and in 11 patients who received CMS. Time to recurrent biliary obstruction (RBO) and survival time did not differ significantly between the two groups (P  = 0.84 and P = 0.29, respectively). However, tumor size at 2 months after stent insertion was significantly decreased in patients in the MSCPM-III group with bile duct cancers or those who experienced stent migration compared with the CMS group. Complications, including cholangitis and pancreatitis, were found to be acceptable in both groups. Conclusions Although compared with a CMS the MSCPM-III did not significantly influence time to RBO or survival duration in patients with malignant biliary obstructions, MSCPM-III reduced tumor volume and was used safely in humans.

[1]  Myung-Hwan Kim,et al.  Efficacy of a Multiplex Paclitaxel Emission Stent Using a Pluronic® Mixture Membrane versus a Covered Metal Stent in Malignant Biliary Obstruction: A Prospective Randomized Comparative Study , 2017, Gut and liver.

[2]  Su Yeon Lee,et al.  Molecular Mechanism of Local Drug Delivery with Paclitaxel-Eluting Membranes in Biliary and Pancreatic Cancer: New Application for an Old Drug , 2015, Gastroenterology research and practice.

[3]  Dong Ki Lee,et al.  Nonvascular drug-eluting stent coated with sodium caprate-incorporated polyurethane for the efficient penetration of paclitaxel into tumor tissue , 2015, Journal of biomaterials applications.

[4]  T. Itoi,et al.  TOKYO criteria 2014 for transpapillary biliary stenting , 2015, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[5]  Jun Wu,et al.  Antireflux stents to reduce the risk of cholangitis in patients with malignant biliary strictures: a randomized trial , 2014, Endoscopy.

[6]  A. Barkun,et al.  No benefit of covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction: a meta-analysis. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  Jie Hyun Kim,et al.  Efficacy of a Metallic Stent Covered with a Paclitaxel-Incorporated Membrane Versus a Covered Metal Stent for Malignant Biliary Obstruction: A Prospective Comparative Study , 2013, Digestive Diseases and Sciences.

[8]  Jie Hyun Kim,et al.  Porcine feasibility and safety study of a new paclitaxel-eluting biliary stent with a Pluronic-containing membrane , 2012, Endoscopy.

[9]  J. I. Lee,et al.  The Biodurability of Covering Materials for Metallic Stents in a Bile Flow Phantom , 2012, Digestive Diseases and Sciences.

[10]  M. Murad,et al.  Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. , 2011, Gastrointestinal endoscopy.

[11]  S. Yun,et al.  Paclitaxel-eluting covered metal stents versus covered metal stents for distal malignant biliary obstruction: a prospective comparative pilot study. , 2010, Gastrointestinal endoscopy.

[12]  S. Misra,et al.  Reflux of duodenal contents and cholangitis in patients undergoing self-expanding metal stent placement. , 2009, Gastrointestinal endoscopy.

[13]  Ho-Young Song,et al.  Histologic influence of paclitaxel-eluting covered metallic stents in a canine biliary model. , 2009, Gastrointestinal endoscopy.

[14]  N. Sasahira,et al.  Management of distal malignant biliary obstruction with the ComVi stent, a new covered metallic stent , 2009, Surgical Endoscopy.

[15]  Dong Ki Lee,et al.  Human application of a metallic stent covered with a paclitaxel-incorporated membrane for malignant biliary obstruction: multicenter pilot study. , 2007, Gastrointestinal endoscopy.

[16]  Eithne Costello,et al.  Biology and management of pancreatic cancer , 2007, Postgraduate Medical Journal.

[17]  V. G. Rao,et al.  Impact of reducing duodenobiliary reflux on biliary stent patency: an in vitro evaluation and a prospective randomized clinical trial that used a biliary stent with an antireflux valve. , 2007, Gastrointestinal endoscopy.

[18]  J. Kim,et al.  Covered versus uncovered wallstent for malignant extrahepatic biliary obstruction: a cohort comparative analysis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  N. Sasahira,et al.  Efficacy and safety of the covered Wallstent in patients with distal malignant biliary obstruction. , 2005, Gastrointestinal endoscopy.

[20]  J van Marle,et al.  Mechanisms of biliary stent clogging: confocal laser scanning and scanning electron microscopy. , 2005, Endoscopy.

[21]  Dong Ki Lee,et al.  The effect on porcine bile duct of a metallic stent covered with a paclitaxel-incorporated membrane. , 2005, Gastrointestinal endoscopy.

[22]  T. Iwai,et al.  Efficacy of a glycyrrhizin suppository for the treatment of chronic hepatitis C: a pilot study. , 2003, Hepatology Research.

[23]  M. Kalinowski,et al.  Paclitaxel Inhibits Proliferation of Cell Lines Responsible for Metal Stent Obstruction:: Possible Topical Application in Malignant Bile Duct Obstructions , 2002, Investigative radiology.

[24]  Dong Ki Lee,et al.  Features of malignant biliary obstruction affecting the patency of metallic stents: a multicenter study. , 2002, Gastrointestinal endoscopy.

[25]  P. Cotton,et al.  Randomised trial of endoscopic steriting versus surgical bypass in malignant low bileduct obstruction , 1994, The Lancet.

[26]  K. Klose,et al.  Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial. , 1993, Endoscopy.

[27]  K. Hausegger,et al.  Malignant biliary obstruction: histologic findings after treatment with self-expandable stents. , 1992, Radiology.

[28]  A. Kruse,et al.  Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. , 1989, Gut.